References Baytril®



(1) Blondeau JM. Steps To Antimicrobial Therapy. 2nd edition. North American Compendiums Inc. 2014, page 135
(2) Ihrke PJ: Bacterial skin disease in the dog: a guide to canine pyoderma. Veterinary Learning Systems Kansas USA, 1996.
(3) Muller GH, Kirk RW, Scott DW: Bacterial Skin Diseases, in Muller GH, Kirk RW, Scott DW: Small Animal Dermatology, ed 4, W.B. Saunders Company Philadelphia: 211–246, 1989.
(4) Aucoin DP: Target, the antimicrobial reference guide to effective treatment. North American Compendiums Inc., 1993.
(5) King LG, Boothe DM: Bacterial infections of the respiratory tract in dogs and cats. Veterinary Learning Systems Kansas USA, 1997.
(6) Breitschwerdt EB, Davidson MG, Aucoin DP, Levy MG, Szabados NS, Hegarty BC, Kuehne AL, James, RL: Efficacy of chloramphenicol, enrofloxacin and tetracycline for treatment of experimental Rocky Mountain Spotted Fever in dogs. Antimicrobial Agents and Chemotherapy, 11: 2,375–2,381, 1991.
(7) Kontos VI, Athanasiou LV: Use of enrofloxacin in the treatment of acute canine ehrlichiosis. Canine Practice 23 (3): 10–14, 1998.
(8) Lindenstruth H, Frost JW: Enrofloxacin (Baytril®) eine Alternative in der Psittakoseprophylaxe und -therapie bei importierten Psittaciden. Dtsch. tierärztl. Wschr. 100 (9): 364–368, 1993.
(9) Studdert VP, Hughes KL: Treatment of opportunistic mycobacterial infections with enrofloxacin in cats. JAVMA 201 (9): 1,388–1,390, 1992.
(10) Evans LM, Caylor KB: Mycobacterial lymphadenitis in a cat. Feline Practice 23 (4): 14–17, 1995.
(11) Wetzstein HG, DeJong A: In vitro bactericidal activity and post-antibiotic effect of fluoroquinolones used in veterinary medicine. Suppl Compend Contin Educ Pract Vet 18 (2): 22–29, 1996.
(12) Pirro F, Edingloh M, Schmeer N: Bactericidal and inhibitory activity of enrofloxacin and other fluoroquinolones in small animal pathogens: Suppl Compend Contin Educ Pract Vet 21 (12): 19–25, 1999.
(13) Brown SA: Fluoroquinolones in animal health. J vet Pharmacol Therap 19: 1–14, 1996.
(14) Küng K, Wanner M: Einfluß zweier verschiedener Futter auf die Pharmacokinetik von oral appliziertem Baytril® (Enrofloxacin) beim Hund. Kleintierpraxis 38, 2: 95–102, 1993.
(15) Aucoin DP: Intracellular-intraphagocytic dynamics of fluoroquinolone antibiotics: a comparative review. Suppl Compend Contin Educ Pract Vet 18 (2): 9–13, 1996.
(16) Petzinger E: Gyrasehemmstoffe, eine neue Klasse von Chemotherapeutika. Tierärztl Prax 19: 14–20, 1991.
(17) Monlouis JD, DeJong A, Limet A, Richez P: Plasma pharmacokinetics and urine concentrations after oral administration of enrofloxacin to dogs. Proceedings 7th EAVPT Congress, Madrid: J vet Pharmacol Therap 20 (Suppl 1): 61–63, 1997.
(18) Altreuther P: Safety and tolerance of enrofloxacin in dogs and cats. Proceedings 1st Int. Symposium on Baytril®: 15–19, 1992
(19) Gelatt KN, van der Woerdt A, Ketring KL, Andrew SE, Brooks DE, Biros BJ, Denis HM, Cutler TJ. Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol 2001; 4:99–106.
(20) Wiebe V, Hamilton P. Fluoroquinolone-induced retinal degeneration in cats. JAVMA, 2002; 221(11):1,568–1,571.
(21) Ramirez CJ, Minch JD, Gay JM, Lahmers SM, Guerra DJ, Haldorson GJ, Schneider T, Mealey KL. Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats. Pharmacogenet Genomics, 2011; 21:66–75
(22) Messias A, Gekeler F, Wegener A, Dietz K, Kohler K, Zrenner E. Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with eletroretinography. Doc Ophthalmol 2008; 116:177–191
(23) Grauer GF: Urinary Tract Infections, in Allen DG (ed): Small Animal Medicine, Lippincott, Philadelphia: 625–655, 1991.
(24) Barsanti JA: Prostatic infections: diagnosis and therapy. Selected proceedings from the scientific program of The North American Veterinary Conference, Orlando: 40–49, 1998.
(25) Boothe DM: Enrofloxacin revisited. Veterinary Medicine 8: 744–753, 1994.